MYC and pancreatic adenocarcinoma: In the case of PANC1 pancreatic adenocarcinoma cells treated with c‐Myc inhibitors at a 25 μM final dose, four compounds c‐Myc‐i7, c‐Myc‐i8, c‐Myc‐i10 and c‐Myc‐i12 displayed substantial reductions in cell viability, exceeding 50% and outperforming the reference compound 10058‐F4 (Figure 1B).